Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
Items 401–500 of 1,000
Januzzi, J. L., Tan, X., Yang, L., Brady, J. E., Yang, M., Banka, P., & Lautsch, D. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13749 · Cited by 13
Vericiguat reduces electrical and structural remodeling in a rabbit model of atrial fibrillation
Lou, Q., Li, L., Liu, G., Li, T., Zhang, L., Zang, Y., Zhan, C., Wang, H., & Li, W. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231185252 · Cited by 14
“8 This has been found to enhance both vascular and myocardial function and reverse hypertrophy and fi brosis of the left ventricle, as well as reduce ventricular remodeling and afterload by the modulation of both pulmonary and systemic vasodilation, and has been used for treating HF. 9 The trials…”
BackgroundArmijo, J. P., Aguilera, J. L., Manzanares, R. G., Pericet-Rodríguez, C., Castillo, J. C., Campos, G. M. H., Roldán-Guerra, Á., Urbano-Sánchez, C., Mesa, L. B., Caño, N. A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186082 · Cited by 14
“In the different clinical trials of treatments with prognostic benefit in HFrEF, a prevalence of 15–30% of WHF has been observed during follow-up [4–6], which is consistent with the findings of other studies [1].”
Zavaleta‐Monestel, E., Arguedas‐Chacón, S., Quirós-Romero, A., Chaverri‐Fernández, J. M., Arias, B. S., Díaz‐Madriz, J. P., García-Montero, J., & Speranza, M. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0022 · Cited by 18
“19,36,37) The follow-ups from the clinical pharmacist during the different titration periods can play a crucial role in achieving goal doses early or treating the patients according to their tolerability.”
BackgroundRecurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction
Mentz, R. J., Stebbins, A., Butler, J., Chiang, C., Ezekowitz, J. A., Hernandez, A. F., Hilkert, R. J., Lam, C. S. P., McDonald, K., O’Connor, C. M., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2023.12.005 · Cited by 14
Self-citationFehér, A., Bednarski, B. P., Miller, R. J. H., Shanbhag, A. D., Lemley, M. H., Miras, L., Sinusas, A. J., Miller, E. J., & Slomka, P. J. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266761 · Cited by 16
“This could also include invasive hemodynamic monitoring ( 34 ) and targeted prescribing of medications shown to reduce HF hospitalizations in high-risk populations ( 35 ).”
BackgroundImplementation of Guideline-Recommended Medical Therapy for Patients with Heart Failure in Europe
Volterrani, M., Seferovic, P., Savarese, G., Spoletini, I., Imbalzano, E., Bayés‐Genís, A., Jankowska, E. A., Senni, M., Metra, M., Chioncel, O. D., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15105 · Cited by 20
“3 This class 2b recommendation is based on data from the VICTORIA study, 44 which assessed the ef fi cacy and safety of vericiguat in a high-risk population with HFrEF post-worsening HF events who were optimized on background HF therapy.”
Acute Heart Failure and Non-Ischemic Cardiomyopathies: A Comprehensive Review and Critical Appraisal
Manzi, L., Buongiorno, F., Narciso, V., Florimonte, D., Forzano, I., Castiello, D. S., Sperandeo, L., Paolillo, R., Verde, N., Spinelli, A. M., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15050540 · Cited by 20
“…usual care on mortality and heart failure rehospitalization among patients with acute heart failure), and VICTORIA (vericiguat in patients with heart failure and reduced ejection fraction) trials, there are no data on differences in outcomes between ischemic vs. non-ischemic HF patients [33–35].”
Chen, Y.-J., Chien, C., Chiang, C., Chen, C.-H., & Cheng, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126617 · Cited by 18
“In addition, vericiguat, a novel oral soluble guanylate cyclase stimulator, decreased the incidence of death from cardiovascular causes or hospitalization among patients with high-risk HF [13].”
BackgroundImpact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure
Rao, B., Speight, C. D., Allen, L. A., Halpern, S. D., Ko, Y., Matlock, D. D., Moore, M. A., Morris, A. A., Scherer, L. D., Thomson, M. C., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023789 · Cited by 15
Correale, M., Mazzeo, P., Tricarico, L., Croella, F., Fortunato, M., Magnesa, M., Amatruda, M., Alfieri, S., Ferrara, S., Ceci, V., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01166-2 · Cited by 14
“Based on the results of the VICTORIA study [120], vericiguat (oral soluble guanylate cyclase receptor stimulator) may be considered in patients according to guidelines [110] in New York Heart Association Class II–IV with worsening HF despite treatment with ACEi (or ARNI), β-blocker and MRA to reduce the risk of cardio…”
MethodThe Role of Mitochondria in Metabolic Syndrome–Associated Cardiomyopathy
Li, J., Li, J., Chen, Y., Hu, W., Gong, X., Qiu, H., Chen, H., Xin, Y., & Li, H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9196232 · Cited by 18
“Another FDA-approved agent related to oxidative stress is the soluble guanylate cyclase stimulator vericiguat [206].”
Cost effectiveness analyses of pharmacological treatments in heart failure
Lim, A. H., Rahim, N. A., Zhao, J., Cheung, S. Y. A., & Lin, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.919974 · Cited by 19
Praliciguat Promotes Ischemic Leg Reperfusion in Leptin Receptor-Deficient Mice
Foussard, N., Rouault, P., Cornuault, L., Reynaud, A., Buys, E. S., Chapouly, C., Gadeau, A., Couffinhal, T., Mohammedi, K., & Renault, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.322033 · Cited by 17
Böttcher, M., Düngen, H., Vasile, C., Donath, F., Fuhr, R., Gal, P., Mikus, G., Trenk, D., Coenen, M., Pires, P. V., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00557-2 · Cited by 14
Shen, M., Zheng, C., Chen, L., Li, M., Huang, X., He, M., Liu, C.-Y., Lin, H., Liao, W., Bin, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114569 · Cited by 15
Sim, D., Lin, W., Sindone, A. P., Yingchoncharoen, T., Prameswari, H. S., Ghazi, A. M., Pin, L. C., Teo, L. L. Y., Aw, T. C., Agbayani, M. F., et al. (2023) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2022.42 · Cited by 14
Modulation of Redox-Sensitive Cardiac Ion Channels
Orfali, R., El-Din, A. H. G., Karthick, V., Lamis, E., Xiao, V., Ramanishka, A., Alwatban, A., Alkhamees, O. A., Alaseem, A. M., Nam, Y.-W., et al. (2025) · Antioxidants · doi:10.3390/antiox14070836 · Cited by 18
“An alternative approach utilizes soluble guanylate cyclase (sGC) stimulators such as vericiguat to increase cGMP signaling, thereby conferring redox protection and vasodilation [120].”
Soluble Guanylate Cyclase Stimulators in Heart Failure
Kansakar, S., Guragain, A., Verma, D., Sharma, P., Dhungana, B., Bhattarai, B., Yadav, S. K., & Gautam, N. (2021) · Cureus · doi:10.7759/cureus.17781 · Cited by 15
“[27] 2020 VICTORIA NCT 02861534 5050 To assess the effect of vericiguat on death from cardiovascular causes or HHF in patients with HFrEF.”
BackgroundTrujillo, M. E., Arrington, L., Patel, Y. T., Passarell, J. A., Wenning, L. A., Blaustein, R. O., Armstrong, P. W., Meyer, M. C., Becker, C., & Gheyas, F. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2712 · Cited by 13
“4% in the placebo group were receiving the target 10mg dose.(1) This suggests that a patient’s ability to titrate to and maintain the target dose is likely not dependent on difference in patient- specific drug clearance, leading to differences in vericiguat exposure.”
BackgroundMethodResultSelf-citationBánfi‐Bacsárdi, F., Muk, B., Pilecky, D., Duray, G. Z., Kiss, R. G., & Nyolczas, N. (2022) · Cardiology · doi:10.1159/000528505 · Cited by 17
Mustafa, D. M., Magdy, N., & Azab, N. F. E. (2023) · Talanta · doi:10.1016/j.talanta.2023.124498 · Cited by 13
Bielecka-Dabrowa, A. M., Banach, M., Wittczak, A., Cicero, A. F. G., Kallel, A., Kubilius, R., Mikhailidis, D. P., Sahebkar, A., Stoian, A. P., Vinereanu, D., et al. (2023) · Archives of Medical Science · doi:10.5114/aoms/167799 · Cited by 20
“The orally available activator of soluble guanylate cyclase, vericiguat, has been shown to exert beneficial effects in a recent largescale randomized trial [132].”
BackgroundYong, S. J., Halim, A., Halim, M., Ming, L. C., Goh, K. W., Alfaresi, M. S., Alshehail, B. M., Fares, M. A. A., Alissa, M., Sulaiman, T., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2242773 · Cited by 14
Bhat, O. M., Mir, R. A., Nehvi, I. B., Wani, N. A., Dar, A. H., & Zargar, M. A. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101469 · Cited by 18
Consistency of HFrEF treatment effect in underrepresented groups in randomized clinical trials
Baudry, G., Monzo, L., Petrie, M. C., Girerd, N., Piña, I. L., Mebazaa, A., Butler, J., Abid, L., Zannad, F. M., & Spall, H. G. C. V. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00028-4 · Cited by 15
“No signi fi cant age-treatment interaction was observed in recent trials testing the ef fi cacy of vericiguat and omecamtiv mecarbil, as indicated in Table 5 38,39 .”
InfluentialSelf-citationBaris, R. O., & Tabit, C. E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165894 · Cited by 20
“In the VICTORIA study, vericiguat reduced the risk of cardiovascular death or HF hospitalization by 10% compared with placebo in high-risk symptomatic HFrEF patients (HR 0.90; p = 0.02) [77].”
InfluentialCardiac Myosin Activation for the Treatment of Systolic Heart Failure
Bernier, T. D., & Buckley, L. F. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000929 · Cited by 13
Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction
Kim, E.-S., Youn, J., & Baek, S. H. (2020) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2020.2.e17 · Cited by 16
Combined pre- and post-capillary pulmonary hypertension in left heart disease
Riccardi, M., Pagnesi, M., Sciatti, E., Lombardi, C., Inciardi, R. M., Metra, M., & Vizzardi, E. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10251-9 · Cited by 13
“1 3 or cardiovascular mortality in patients with HFrEF in the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial [84].”
BackgroundAiming at harmony. Comparing and contrasting International HFrEF Guidelines
Tomasoni, D., Adamo, M., Bozkurt, B., Heidenreich, P. A., McDonagh, T. A., Rosano, G. M. C., Virani, S., Zieroth, S. R., & Metra, M. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac124 · Cited by 14
“worsening HF despite GDMT to reduce the risk of CV mortality or HF hospitalization with no difference in the CoR and LoE between the two guidelines (CoR IIb, LoE 2b B).(1,2,27)”
BackgroundNovel and emerging therapies in pulmonary arterial hypertension
Cassady, S. J., Soldin, D., & Ramani, G. V. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1022971 · Cited by 14
“The sGC stimulator vericiguat reduced the incidence of death compared to placebo in a cohort of 5,050 patients with heart failure with reduced ejection fraction (less than 45%) in the VICTORIA trial, resulting in its FDA approval for this application (Armstrong et al., 2020).”
MethodVericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial
Lang, N. N., Dobbin, S. J. H., & Petrie, M. C. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa247 · Cited by 13
“ful benefits of soluble guanylate cyclase (sGC) agonism in patients with worsening or high-risk HFrEF.(4) The 5050 patients enrolled in VICTORIA were randomized to placebo or treatment with the sGC stimulator, vericiguat, including a”
InfluentialLeft Heart Disease-Related Pulmonary Hypertension
Alamri, A. K., Ma, C. L., & Ryan, J. J. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.08.007 · Cited by 14
Norre, T., Grimm, D. G., & Simonsen, U. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13714 · Cited by 13
“The vericiguat group experienced fewer HHF or deaths from cardiovascular causes.(50) The effects for the two outcomes separately were HHF (RR: 0.”
BackgroundMethodResultInfluentialVericiguat in Heart Failure with Reduced Ejection Fraction
Wearden, J., Hough, A., & Kaiser, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2027731 · Cited by 15
Self-citationGrant, A. D. M., Chew, D. S., Howlett, J. G., & Miller, R. J. H. (2020) · CJC Open · doi:10.1016/j.cjco.2020.05.009 · Cited by 12
“This is particularly true in light of other major developments in pharmacologic management of HFrEF such as sinus node inhibition,(29) sodium-glucose cotransporter 2 inhibitor therapy,(30) and most recently the soluble guanylate cyclase stimulator vericiguat.(31) Reduction in the price of ARNi would further improve th…”
BackgroundButler, J., Zheng, Y., Khan, M. S., Bonderman, D., Lund, L. H., deFilippi, C. R., Blaustein, R. O., Ezekowitz, J. A., Freitas, C., Hernandez, A. F., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.12.014 · Cited by 12
Self-citationBioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect
Majid, A., Hassan, F. O., Hoque, M. M., Gbadegoye, J. O., & Lebeche, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10070313 · Cited by 16
“Guanylate Cyclase Stimulators: Vericiguat, used in the treatment of heart failure with reduced ejection fraction (HFrEF) [83], has been shown to reduce myocardial ischemic injury in experimental animals and reduce fibrosis biomarkers in cardiac fibrosis in human patients.”
MethodNarayan, S. I., Terre, G. V., Amin, R., Shanghavi, K. V., Chandrashekar, G. S., Ghouse, F., Ahmad, B. A., Gowri, N. S., Satram, C., Majid, H. A., et al. (2023) · Cureus · doi:10.7759/cureus.45719 · Cited by 18
Szabo, T. M., Nagy, E. E., Kirchmaier, Á., Heidenhoffer, E., Gábor-Kelemen, H., Frăsineanu, M., Cseke, J., Germán-Salló, M., & Frigy, A. (2023) · Biomolecules · doi:10.3390/biom13111578 · Cited by 12
“Vericiguat, the oral soluble guanylate cyclase receptor stimulator, not only reduced the composite endpoint of hospitalization for HF or death from cardiovascular causes, but also significantly decreased high-sensitive CRP and serum UA concentrations in patients with HFrEF [60,61].”
BackgroundSpadafora, L., Bernardi, M., Sarto, G., Simeone, B., Forte, M., D’Ambrosio, L., Betti, M., D’Amico, A., Cammisotto, V., Carnevale, R., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00652-6 · Cited by 15
Inciardi, R. M., Vaduganathan, M., Lombardi, C., Gussago, C., Agostoni, P., Ameri, P., Aspromonte, N., Calò, L., Cameli, M., Carluccio, E., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3260 · Cited by 13
Tang, H., Germinal, K., Milfort, A., Chen, W., Chang, S., Huang, W., Li, Y., Lu, Y., Ahmed, M. M., Kimmel, S. E., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04339-3 · Cited by 16
Hopper, R. K., Hansmann, G., Hollander, S. A., Dipchand, A. I., van der Have, O., Iler, C. M., Herrington, C. S., Rosenzweig, E. B., Alejos, J. C., & Tran‐Lundmark, K. (2024) · Circulation Heart Failure · doi:10.1161/hhf.0000000000000086 · Cited by 12
Oliva, F. G., Orso, F., Colivicchi, F., Cipriani, M., Lenarda, A. D., Gabrielli, D., Gori, M., Gorini, M., Iacoviello, M., Lucci, D., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.019 · Cited by 17
Addressing Cardiovascular Diseases Challenges in South Korea: Strategies to Improve Outcomes
Kang, H., Wang, J., Cho, E. J., Kim, H., Lee, C. J., Park, J. H., Kang, J., Suh, J., Choi, K. H., Lee, S., et al. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2024.0385 · Cited by 13
“86)87) Therefore, future research and attention on medication use in frail elderly patients is needed.”
Chen, C., Zhong, W., Zheng, H., Zhao, W., Wang, Y., & Shen, B. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1518036 · Cited by 12
“Increasing clinical studies have shown that vericiguat can reduce the incidence of cardiovascular death or HF hospitalization (57, 58).”
Jia, X., Rifai, M. A., Liu, J., Agarwala, A., Gulati, M., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00856-6 · Cited by 12
Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives
Popa, I. P., Haba, M. Ș. C., Maranducă, M. A., Tănase, D. M., Șerban, D. N., Șerban, L., Iliescu, R., & Tudorancea, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091964 · Cited by 18
“SOCRATES-REDUCED (Phase IIb Safety and Efficacy Study of Four Dose Regimens of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure) and VICTORIA (Vericiguat in Participants with Heart Failure with Reduced Ejection Fraction) are the two clinical trials…”
BackgroundAdvances in contemporary medical management to treat patients with heart failure
Velez, M. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001021 · Cited by 15
Sharina, I. G., & Martin, E. (2023) · Cells · doi:10.3390/cells12030471 · Cited by 18
“At least two stimulators, riociguat and vericiguat, were approved as SGC-targeting therapeutics for the management of pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension [58,59], and heart failure conditions [60,61].”
BackgroundVericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
Falco, L., Brescia, B., Catapano, D., Martucci, M. L., Valente, F., Gravino, R., Contaldi, C., Pacileo, G., & Masarone, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10090388 · Cited by 17
“The VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) study was a multinational, double-blind, placebo-controlled phase III RCT [36] that expanded the information gathered in SOCRATES-Reduced.”
MethodAdvances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
Kearney, A., Linden, K., Savage, P., & Menown, I. B. A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01711-z · Cited by 14
Allen, L. A., Teerlink, J. R., Gottlieb, S. S., Ahmad, T., Lam, C. S. P., & Psotka, M. A. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008594 · Cited by 12
Self-citationVericiguat en insuficiencia cardíaca: de la evidencia científica a la práctica clínica
González‐Juanatey, J. R., Anguita-Sánchez, M. P., Bayés‐Genís, A., Colet, J. C., Quintana, A. G., Mayoral, A. R., Zamorano-Gómez, J. L., Cepeda-Rodrigo, J. M., & Manzano, L. (2022) · Revista Clínica Española · doi:10.1016/j.rce.2021.12.005 · Cited by 15
An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease
Tumelty, E. H., Chung, I., Hussain, S. A., Ali, M. A., Addada, H., & Banerjee, D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504144 · Cited by 13
“The trial capped the number of patients recruited with eGFR of 15– 30 mL/min/1.73 m 2 to 15% of trial total population [173].”
BackgroundInfluentialMuk, B., Pilecky, D., Bánfi‐Bacsárdi, F., Füzesi, T. P., Gergely, T. G., Komáromi, A., Papp, E., Szőnyi, M. D., Forrai, Z., Kazay, Á., et al. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33045 · Cited by 15
Blood pressure and heart failure: focused on treatment
Chun, K., & Kang, S. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00271-y · Cited by 16
Greene, S. J., Corda, S., McMullan, C. J., Palombo, G., Schooss, C., Vlajnic, V., Walkamp, K., & Senni, M. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3699 · Cited by 11
What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Khan, M. S., & Vaduganathan, M. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01347-3 · Cited by 12
Impact of Geographic Region on the COMMANDER-HF Trial
Ferreira, J. P., Cleland, J. G. F., Lam, C. S. P., van Veldhuisen, D. J., Byra, W. M., Police, D. A. L., Anker, S. D., Mehra, M. R., Leroy, C., Eschwège, V., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2020.11.007 · Cited by 13
Self-citationWong, J. A., Roberts, J. D., & Healey, J. S. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.024 · Cited by 11
Evolving Cardiac Electrical Therapies for Advanced Heart Failure Patients
Sharif, Z. I., Galand, V., Hucker, W. J., & Singh, J. P. (2021) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.120.009668 · Cited by 11
Cvijić, M., Rib, Y., Danojevic, S., Radulescu, C.-I., Nazghaidze, N., & Vardas, P. E. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10267-1 · Cited by 16
Jiao, T., Collado, A., Mahdi, A., Tengbom, J., Tratsiakovich, Y., Milne, G. T., Alvarsson, M., Lundberg, J. O., Zhou, Z., Yang, J., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.02.017 · Cited by 14
Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947
Brockunier, L. L., Stelmach, J. E., Guo, J., Spencer, T. W., Rosauer, K. G., Bansal, A., Cai, S., Chen, N., Cummings, J. G., Huang, L., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127574 · Cited by 13
Heart Failure With Midrange Ejection Fraction—What Is It, If Anything?
Boulet, J., Massie, E., & Rouleau, J. L. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.11.013 · Cited by 14
Galati, G., Андреевна, Г. О., Iozzo, R. V., Buraschi, S., Shchukin, Y. V., Germanov, A. V., Germanov, V. A., Терешина, О. В., Senni, M., & Margonato, A. (2021) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.21.05786-0 · Cited by 12
Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides
Zhu, K., Ma, T., Su, Y., Pan, X., Huang, R., Zhang, F., Yan, C., & Xu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.683418 · Cited by 11
Repetitive milrinone therapy in ambulatory advanced heart failure patients
Laufer‐Perl, M., Sadon, S., Zahler, D., Milwidsky, A., Sadeh, B., Sapir, O. P. R., Granot, Y. N., Korotetski, L., Ketchker, L., Rosh, M., et al. (2022) · Clinical Cardiology · doi:10.1002/clc.23802 · Cited by 10
Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure
Liang, W., & Liang, B. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01884-9 · Cited by 12
(2022) · European Heart Journal · doi:10.1093/eurheartj/ehac775 · Cited by 11
Proposed New Conceptualization for Definition of Decompensated HF
Bozkurt, B. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.02.001 · Cited by 12
N-Heterocycles as Privileged Scaffolds in FDA Approved Different NMEs of 2021: A Review
Chaudhry, F., Munir, R., & Malik, N. (2022) · Letters in Organic Chemistry · doi:10.2174/1570178620666221026095145 · Cited by 11
Meekers, E. M., & Müllens, W. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00591-4 · Cited by 10
Nakamura, M., Imamura, T., & Kinugawa, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134396 · Cited by 12
“Patients with systolic blood pressure below 100 mmHg or those receiving intravenous catecholamine infusion were excluded [2,3].”
BackgroundInfluentialSummary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines
Badger, S., McVeigh, J., & Indraratna, P. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00328-3 · Cited by 14
“The VICTORIA trial found a 10% reduction in the primary outcome (CV death or HF hospitalization) in patients with LVEF \ 45%, NYHA class II-IV, on GDMT with elevated natriuretic peptides and recent HF worsening when taking vericiguat vs. placebo [35].”
MethodSatoh, T., Yaoita, N., Nochioka, K., Tatebe, S., Hayashi, H., Yamamoto, S., Sato, H., Takahama, H., Suzuki, H., Terui, Y., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14515 · Cited by 10
“6 However, to date, most other clinical trials with sGC stimulators for patients with HF, particularly HF with preserved ejection fraction (HFpEF), have been disappointing, 7 – 9 likely due to their heterogeneous aetiologies, such as valvular disease, cardiomyopathies, ischaemic heart disease, or…”
Chen, Q., Huang, Z., Chen, J., Tian, X., Zhang, R., Liang, Q., Liu, Z., & Cheng, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117004 · Cited by 10
Dickert, N. W., Speight, C. D., Balser, M., Biermann, H., Davis, J. K., Halpern, S. D., Ko, Y., Krishnan, A., Matlock, D. D., Mitchell, A. R., et al. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.011273 · Cited by 12
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
“…endpoint of cardiovascular death or first HF hospitalization among individuals with HFrEF and worsening HF (hospitalization in the past 6 months or intravenous diuretics in the past 3 months) at a median follow-up of 10.8 months (35.5% versus 38.5%; HR 0.90; 95% CI 0.82–0.98; P = 0.02) 63 .”
InfluentialVericiguat Improves Cardiac Remodelling and Function in Rats with Doxorubicin-Induced Cardiomyopathy
Chen, W., Wu, Y., Li, J., Song, M., Xu, K., Wu, M., & Lin, L. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15186 · Cited by 11
Noiri, J., Fujimoto, W., Takemoto, M., Kuroda, K., Yamashita, S., Imanishi, J., Iwasaki, M., Todoroki, T., Okuda, M., Nagao, M., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0002 · Cited by 12
“26 The key RCTs excluded patients with eGFR 20– 30 mL/min/1.73 m 2 .”
InfluentialGemfibrozil derivatives as activators of soluble guanylyl cyclase – A structure-activity study
Gayler, K. M., Quintana, J. M., MATTKE, J. D., Plunk, M. A., Kostyo, J. H., Karunananthan, J. W., Nguyen, H., Shuda, M. R., Ferreira, L. D., Baker, H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113729 · Cited by 10
Chimed, S., Stassen, J., Galloo, X., Meucci, M. C., van der Bijl, P., Knuuti, J. M., Delgado, V., Marsan, N. A., & Bax, J. J. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.08.035 · Cited by 8
Nakata, T., Shindo, T., Ito, K., Eguchi, K., Monma, Y., Ichijo, S., Ryoke, R., Satoh, W., Kumasaka, K., Sato, H., et al. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.08.010 · Cited by 14
Nitric oxide and thiols: Chemical biology, signalling paradigms and vascular therapeutic potential
Dent, M. R., & DeMartino, A. W. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16274 · Cited by 14
“…rise to numerous disease pathologies including pulmonary hypertension, peripheral vascular disease, heart failure, atherosclerosis and chronic kidney disease (Armstrong et al., 2020; Bénardeau et al., 2021; Giaid & Saleh, 1995; Li & Förstermann, 2013; Pacher et al., 2007; Stasch et al., 2011).”
Ullah, W., Mukhtar, M., Almukhtar, A., Saeed, R., Boigon, M. I., Haas, D. C., & Rame, J. E. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i10.501 · Cited by 10
Sharina, I. G., Lezgiyeva, K., Krutsenko, Y., & Martin, E. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114459 · Cited by 11
Moghaddam, N., Malhi, N., & Toma, M. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.07.003 · Cited by 10
Vericiguat: A Novel Soluble Guanylate Cyclase Stimulator for Use in Patients With Heart Failure
Gupta, R., Lin, M., Maitz, T., Egeler, D., Sood, A., Aronow, W. S., Rajeswaran, Y., Ahnert, A. M., Vyas, A. V., Frishman, W. H., et al. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000431 · Cited by 10
Sun, K., Kong, F., Lin, F., Li, F., Sun, J., Ren, C., Zheng, B., & Shi, J. (2022) · Mediators of Inflammation · doi:10.1155/2022/1625290 · Cited by 10
“Vericiguat, a novel oral soluble guanylate cyclase (sGC) stimulator, has been firstly reported to reduce the death incidence from cardiovascular causes or hospitalization for heart failure patients in 2020 [13, 14].”
BackgroundTen Lessons from the EMPEROR-Reduced Trial
Butler, J., Zannad, F. M., Filippatos, G. S., Anker, S. D., & Packer, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2009 · Cited by 11
Self-citationThe Real World of de novo Heart Failure: The Next Frontier for Heart Failure Clinical Trials?
Khan, M. S., Butler, J., & Greene, S. J. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1844 · Cited by 10
Self-citationChronic heart failure: epidemiology, investigation and management
Beggs, S. A. S., McDonagh, T. A., & Gardner, R. S. (2022) · Medicine · doi:10.1016/j.mpmed.2022.05.002 · Cited by 8
Kaemmerer, H. M., Baldus, S. E., Baumgartner, H., Berger, F. F., de Haan, F., Frantz, S., Loßnitzer, D., Uebing, A. S., Lebherz, C., Weyand, M., et al. (2023) · Die Kardiologie · doi:10.1007/s12181-023-00616-1 · Cited by 15
Ciccarelli, M., Falcão‐Pires, I., Bauersachs, J. K., Bertrand, L., Beauloye, C., Dawson, D. K., Hamdani, N., Hilfiker‐Kleiner, D., Laake, L. W. V., Lezoualc’h, F., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad088 · Cited by 11
Modulating NO–GC Pathway in Pulmonary Arterial Hypertension
D'Agostino, A. G., Lanzafame, L., Buono, L., Crisci, G., D’Assante, R., Leone, I., Vito, L. D., Bossone, E., Cittadini, A., & Marra, A. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010036 · Cited by 11
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status
Khan, M. S., Butler, J., Young, R., Lewis, B. S., Escobedo, J., Refsgaard, J. C., Reyes, E. B., Roessig, L., Blaustein, R. O., Lam, C. S. P., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.007 · Cited by 13
Self-citation
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.